116 related articles for article (PubMed ID: 26184891)
1. Family History and Relapse in Pediatric Acute Myeloid Leukemia.
Mehrvar A; Tashvighi M; Faranoush M; Reinhardt D; Niktoreh Mofrad N; Hedayati Asl AA; Alebouyeh M
Pediatr Blood Cancer; 2015 Dec; 62(12):2235-7. PubMed ID: 26184891
[TBL] [Abstract][Full Text] [Related]
2. Outpatient ADE (cytarabine, daunorubicin, and etoposide) is feasible and effective for the first relapse of pediatric acute myeloid leukemia: A prospective, phase II study.
Garg A; Ganguly S; Vishnubhatla S; Chopra A; Bakhshi S
Pediatr Blood Cancer; 2020 Sep; 67(9):e28404. PubMed ID: 32672904
[TBL] [Abstract][Full Text] [Related]
3. [Effect of cranial irradiation on rate of recurrence in children with acute myeloid leukemia. Initial results of the AML-BFM-87 study. The AML-BFM Study Group].
Creutzig U; Ritter J; Heyen P; Berthold F; Henze G; Kabisch H; Lampert F; Niethammer D; Riehm H; Schellong G
Klin Padiatr; 1992; 204(4):236-45. PubMed ID: 1518259
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study].
Stahnke K; Ritter J; Schellong G; Beck JD; Kabisch H; Lampert F; Creutzig U
Klin Padiatr; 1992; 204(4):253-7. PubMed ID: 1518261
[TBL] [Abstract][Full Text] [Related]
5. [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].
Reinhardt D; Hempel G; Fleischhack G; Schulz A; Boos J; Creutzig U
Klin Padiatr; 2002; 214(4):188-94. PubMed ID: 12165900
[TBL] [Abstract][Full Text] [Related]
6. Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials.
Alexander TB; Wang L; Inaba H; Triplett BM; Pounds S; Ribeiro RC; Pui CH; Rubnitz JE
Cancer; 2017 Oct; 123(19):3791-3798. PubMed ID: 28556917
[TBL] [Abstract][Full Text] [Related]
7. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.
Creutzig U; Zimmermann M; Reinhardt D; Dworzak M; Stary J; Lehrnbecher T
J Clin Oncol; 2004 Nov; 22(21):4384-93. PubMed ID: 15514380
[TBL] [Abstract][Full Text] [Related]
8. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group.
Kaspers GJ; Zimmermann M; Reinhardt D; Gibson BE; Tamminga RY; Aleinikova O; Armendariz H; Dworzak M; Ha SY; Hasle H; Hovi L; Maschan A; Bertrand Y; Leverger GG; Razzouk BI; Rizzari C; Smisek P; Smith O; Stark B; Creutzig U
J Clin Oncol; 2013 Feb; 31(5):599-607. PubMed ID: 23319696
[TBL] [Abstract][Full Text] [Related]
9. [Improved treatment results in children with AML: Results of study AML-BFM 93].
Creutzig U; Berthold F; Boos J; Fleischhack G; Gadner H; Gnekow A; Graubner U; Henze G; Hermann J; Imbach P; Jürgens H; Kabisch H; Körholz D; Niemeyer CM; Reinhardt D; Reiter A; Ritter J; Spaar HJ; Zimmermann M;
Klin Padiatr; 2001; 213(4):175-85. PubMed ID: 11528551
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98.
von Neuhoff C; Reinhardt D; Sander A; Zimmermann M; Bradtke J; Betts DR; Zemanova Z; Stary J; Bourquin JP; Haas OA; Dworzak MN; Creutzig U
J Clin Oncol; 2010 Jun; 28(16):2682-9. PubMed ID: 20439630
[TBL] [Abstract][Full Text] [Related]
11. Treating childhood acute myeloid leukaemia with the AML-BFM-83 protocol: experience in a developing country.
Chan LL; Abdel-Latif ME; Ariffin WA; Ariffin H; Lin HP
Br J Haematol; 2004 Sep; 126(6):799-805. PubMed ID: 15352983
[TBL] [Abstract][Full Text] [Related]
12. Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the Children's Oncology Group.
Sung L; Aplenc R; Alonzo TA; Gerbing RB; Gamis AS;
Haematologica; 2012 Nov; 97(11):1770-3. PubMed ID: 22801969
[No Abstract] [Full Text] [Related]
13. [Treatment results of acute nonlymphocytic leukemia in childhood--Kyushu Yamaguchi Children's Cancer Study Group].
Ikuno Y; Okamura J; Ishii E; Matuzaki A; Ueda K; Eguchi H; Inada H; Nibu K; Koga H; Miyazaki S
Rinsho Ketsueki; 1995 Apr; 36(4):325-33. PubMed ID: 7783338
[TBL] [Abstract][Full Text] [Related]
14. Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study.
Taga T; Shimomura Y; Horikoshi Y; Ogawa A; Itoh M; Okada M; Ueyama J; Higa T; Watanabe A; Kanegane H; Iwai A; Saiwakawa Y; Kogawa K; Yamanaka J; Tsurusawa M
Pediatr Blood Cancer; 2011 Jul; 57(1):36-40. PubMed ID: 21557456
[TBL] [Abstract][Full Text] [Related]
15. High-dose cytarabine-based consolidation shows superior results for older AML patients with intermediate risk cytogenetics in first complete remission.
Hassanein M; Atenafu EG; Schuh AC; Yee KW; Minden MD; Schimmer AD; Gupta V; Brandwein JM
Leuk Res; 2013 May; 37(5):556-60. PubMed ID: 23357460
[TBL] [Abstract][Full Text] [Related]
16. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group.
Ravindranath Y; Yeager AM; Chang MN; Steuber CP; Krischer J; Graham-Pole J; Carroll A; Inoue S; Camitta B; Weinstein HJ
N Engl J Med; 1996 May; 334(22):1428-34. PubMed ID: 8618581
[TBL] [Abstract][Full Text] [Related]
17. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.
Creutzig U; Reinhardt D; Diekamp S; Dworzak M; Stary J; Zimmermann M
Leukemia; 2005 Aug; 19(8):1355-60. PubMed ID: 15920490
[TBL] [Abstract][Full Text] [Related]
18. Increased mortality with FLA compared with ADE chemotherapy in high-risk AML.
Lane SW; Marlton P; Mollee PN
Blood; 2006 Dec; 108(12):3950-1; author reply 3951. PubMed ID: 17114571
[No Abstract] [Full Text] [Related]
19. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.
Burnett AK; Russell NH; Hills RK; Hunter AE; Kjeldsen L; Yin J; Gibson BE; Wheatley K; Milligan D
J Clin Oncol; 2013 Sep; 31(27):3360-8. PubMed ID: 23940227
[TBL] [Abstract][Full Text] [Related]
20. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
